Drug Trial Radar · NCT04639466
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Nov 19, 2020
Primary completion
Oct 31, 2025
Study completion Dec 3, 2025
Sponsor
- Lead sponsor
- GeoVax, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of the Phase 1 study is to determine the safety and the optimal dose of the GEO-CM04S1 vaccine. The Phase 2 study is designed as a multi-center, double-blind, randomized, parallel, study to evaluate the safety profile of 2 dose levels of GEO-CM04S1 as a single booster shot to assess the immune response measured by the fold-increase in antibody against SARS-CoV-2 Spike protein at day 28 post-injection among healthy adult volunteers.
Conditions
- COVID-19 Infection
Interventions
Placebo AdministrationDrug
Given IM in the non-dominant upper arm
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1Biological
Given IM in the non-dominant upper arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (Phase I)Time frame: Up to 365 days
- Incidence of adverse events (Phase II)Time frame: Within the first 7 days following booster injection
- Antibody levels to SARS CoV-2 Spike protein (Phase II)Time frame: Up to 365 days
- Fold increase of Spike IgG levels (Phase II)Time frame: At 28 days post-injection
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
EmVenio Research
Claremont, California
City of Hope Comprehensive Cancer Center
Duarte, California
Millennium Clinical Trials
Thousand Oaks, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.